Golden Helix
Golden Helix is a private bioinformatics company, founded in 1998 in Bozeman, Montana, that develops ISO 13485-certified clinical variant analysis and interpretation software (VarSeq, VSWarehouse) for diagnostic laboratories, hospitals, and genome centers running NGS workflows.
- Company typePrivate
- Founded1998
- HeadquartersBozeman, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Golden Helix does
Golden Helix is a privately held bioinformatics software company founded in 1998 and headquartered in Bozeman, Montana. The company develops clinical-grade software for next-generation sequencing (NGS) variant analysis, interpretation, and reporting, serving diagnostic laboratories, hospitals, and genome centers. Its portfolio is anchored by the VarSeq Suite (clinical variant analysis with automated ACMG and AMP guideline workflows), VSWarehouse (enterprise genomic data management), and specialized modules including VSClinical, VSPGx for pharmacogenomics, VS-CNV for copy number variation detection, and VSPipeline for workflow automation, with Sentieon integrated for secondary alignment and variant calling.
The platform supports deployment on-premises, in private cloud, or fully air-gapped environments, with the company explicitly stating that patient data never leaves the customer's infrastructure. The software is developed under an ISO 13485:2016-certified quality management system, and VarSeq Suite is declared compliant with the EU In Vitro Diagnostic Regulation (IVDR) as a Class A medical device. Product development is supported by NIH SBIR grant funding, including a $400,000 award in September 2023 and a $2.2 million award in October 2025, both directed at pharmacogenomics capabilities.
Golden Helix monetizes primarily through annual term software licenses (Single Named User, Lab, Server/Cluster, and Site tiers) and introduced usage-based licensing alongside the VarSeq 3 and VSWarehouse 3 releases in November 2025. A separate Japan office in Nagoya supports Asia-Pacific distribution, and the company maintains a direct enterprise sales motion with "Request Evaluation" and "Request Demo" calls to action targeting clinical genomics buyers. The company has no publicly disclosed revenue, no venture capital funding, and operates with an estimated 11-50 employees across its two offices.
Golden Helix firmographics
Firmographics- Name
- Golden Helix
- Legal name
- Golden Helix, Inc.
- Website
- https://goldenhelix.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Golden Helix is a private bioinformatics company, founded in 1998 in Bozeman, Montana, that develops ISO 13485-certified clinical variant analysis and interpretation software (VarSeq, VSWarehouse) for diagnostic laboratories, hospitals, and genome centers running NGS workflows.
- Ownership category
- akta.pro rank
Golden Helix industry classification
Industry- Product category
- Clinical Genomics Software
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)
Keywords
Where Golden Helix is headquartered
LocationHeadquarters
- HQ city
- Bozeman
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Golden Helix business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Software Licenses: Annual software licenses for VarSeq Suite, VSWarehouse, SVS, and GenomeBrowse. Licenses include Single Named User, Lab, Server, Cluster/Concurrent, and Site License options.
- Usage-based Licensing: VarSeq 3 and VSWarehouse 3 introduced usage-based licensing options alongside traditional licensing models.
- Command Line Access: Command line access add-on for VarSeq Suite, sold as an additional license component.
- Professional Services: Training, support, and professional services for implementation and optimization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Single Named User License - For individual use on one computer |
| Subscription | Annual | Lab License - For kiosk-style use by any individual in organization |
| Subscription | Annual | Server/Cluster License - Concurrent access for multiple users |
| Subscription | Multi-year contract | Site License - Multi-machine deployment |
| Freemium | Multi-year contract | GenomeBrowse Standalone - Non-commercial research use |
| Usage-based | Pay-as-you-go | Usage-based Licensing |
| Freemium | Pay-as-you-go | Evaluation License |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
Golden Helix product offering
Product offeringCore offering
Golden Helix sells clinical variant analysis and interpretation software for next-generation sequencing (NGS) workflows, anchored by the VarSeq Suite platform. The software supports germline, oncology, prenatal, and pharmacogenomics applications for diagnostic laboratories, hospitals, and genome centers, with flexible on-premises, private cloud, and air-gapped deployment models.
Product overview
Golden Helix offers a unified clinical genomics platform centered on VarSeq Suite, an integrated software system for clinical variant analysis and interpretation. The portfolio includes VSWarehouse for enterprise genomic data management and Sentieon for secondary analysis. Supporting products include SVS for research, GenomeBrowse for visualization, and specialized modules like VSClinical for ACMG/AMP clinical workflows, VS-CNV for copy number analysis, and VSPGx for pharmacogenomics. The platform supports deployment on-prem, in private cloud, or air-gapped environments, providing diagnostic laboratories, hospitals, and genome centers with scalable variant interpretation across germline, oncology, prenatal, and pharmacogenomics applications.
Differentiator
Problem solved
Functional benefit
Brands
- VarSeq Suite: Clinical variant analysis, interpretation, and reporting platform for genomic data.
- VSWarehouse
- SNP & Variation Suite (SVS)
- GenomeBrowse
- VSClinical
- VSPGx
Products and services
- VarSeq Suite Clinical variant analysis, interpretation, and reporting platform for diagnostic laboratories, hospitals, and genome centers. Supports germline, oncology, prenatal, and pharmacogenomics workflows from targeted panels to whole genomes with integrated interpretation, automation, and data management capabilities.
- VSWarehouse Enterprise genomic data management platform for scalable clinical and research programs. Provides server-based infrastructure for managing genomic data at scale across an organization.
- SNP & Variation Suite (SVS) Research software for GWAS, PCA, association testing, and genomic analysis features. Intended for Research Use Only, not for diagnostic procedures.
- Golden Helix GenomeBrowse Visualization tool for genomic data viewing and analysis, including BAM file visualization, coverage tracks, and variant display. Free for non-commercial internal research purposes.
Quantifiable outcome
- VarSeq enables streamlined clinical variant analysis reducing laboratory workflow complexity
- +1 more outcomes
Companies that use Golden Helix
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Golden Helix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature8 records
Golden Helix partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Austrian Human Genetics LabscoreMulti-year strategic agreement with Austria's public medical genetics labs to enhance genomic diagnostics and research capabilities across six centers. Golden Helix's bioinformatics technologies are being integrated into Austria's healthcare infrastructure to support cancer and hereditary disease diagnostics.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Golden Helix competitors and assessment
Company assessmentBroad incumbents
- QIAGEN (QIAgen Clinical Insight / QCI): QIAGEN's QCI Interpret is one of the most direct commercial competitors in clinical variant interpretation for hereditary and oncology workflows. It is a much larger, publicly traded incumbent with broader product portfolio and global commercial reach.
- Illumina (BaseSpace / DRAGEN): Illumina offers BaseSequence and DRAGEN-based secondary and tertiary analysis solutions, plus its own variant interpretation offerings, representing a vertically integrated incumbent competing in the same clinical variant analysis workflow that VarSeq addresses.
Direct peers
- SOPHiA Genetics: SOPHiA Genetics offers a clinical genomics platform (SOPHiA DDM) used by hospitals and labs for variant interpretation across hereditary and somatic applications, with a strong European footprint that overlaps with Golden Helix's IVDR-positioned market.
- Fabric Genomics: Fabric Genomics provides AI-driven clinical interpretation software for hereditary disease and oncology NGS, directly competing with VarSeq in clinical variant classification and reporting workflows for diagnostic labs.
- Congenica: Congenica offers a clinical genomic data analysis platform for rare disease and inherited disorder interpretation, directly comparable to VarSeq's germline and hereditary disease workflows and target customer base of clinical labs.
- GenomOncology: GenomOncology provides clinical decision support and variant interpretation software for precision oncology workflows, directly overlapping with VarSeq's cancer/AMP-aligned clinical interpretation capabilities.
- Velsera (formerly Seven Bridges Genomics): Velsera operates a clinical genomics platform supporting NGS analysis, interpretation, and data management for clinical and research customers, competing with both VarSeq and VSWarehouse in the clinical genomics software layer.
- PierianDx (now part of Tempus): PierianDx, now part of Tempus, provided clinical genomic interpretation software for hereditary and somatic workflows, directly comparable to VarSeq's clinical interpretation capabilities and customer base of hospital and reference labs.
Emerging players
- DNAnexus: DNAnexus provides a cloud-based biomedical data analysis and clinical genomics platform, overlapping with Golden Helix on secondary and tertiary analysis infrastructure, though with a more cloud-native architecture model.
Others
- Sentieon: Sentieon is both a partner and adjacent provider of high-performance secondary analysis (alignment and variant calling) for NGS workflows integrated into Golden Helix's platform; it represents both a complementary technology and a potential competitor if it expands into tertiary interpretation.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Golden Helix social profiles
Digital presenceGolden Helix compliance and trust
Trust signalCompliance2 records
Golden Helix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Golden Helix leadership team
Management profileNumber of profiles
Profiles1 record
Golden Helix funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Golden Helix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Golden Helix
What does Golden Helix do?
Golden Helix sells clinical variant analysis and interpretation software for next-generation sequencing (NGS) workflows, anchored by the VarSeq Suite platform. The software supports germline, oncology, prenatal, and pharmacogenomics applications for diagnostic laboratories, hospitals, and genome centers, with flexible on-premises, private cloud, and air-gapped deployment models.
Is Golden Helix a public or private company?
Golden Helix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Golden Helix founded?
Golden Helix was founded in 1998. It employs 11 to 50 people.
Where is Golden Helix based?
Golden Helix is headquartered in Bozeman, United States, in the North America region.
How does Golden Helix make money?
Four revenue lines are on record. Software Licenses are the primary driver. The others are usage-based Licensing, command Line Access and professional Services.
Who are Golden Helix's main competitors?
Broad incumbents on record are QIAGEN (QIAgen Clinical Insight / QCI) and Illumina (BaseSpace / DRAGEN). Direct peers are SOPHiA Genetics, Fabric Genomics, Congenica, GenomOncology, Velsera (formerly Seven Bridges Genomics) and PierianDx (now part of Tempus). DNAnexus is listed as an emerging player. Sentieon is listed as an others.
Does Golden Helix have an API?
No public API is recorded for Golden Helix.
What industry is Golden Helix in?
Golden Helix's product category is Clinical Genomics Software. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 5132 and its SIC code is 7372.